Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
November 12, 2021 07:10 ET
|
Vir Biotechnology, Inc.
– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – – The...
ONTF INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ON24, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ONTF
November 10, 2021 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 05:55 ET
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
November 09, 2021 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
November 09, 2021 08:35 ET
|
Novan, Inc.
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...
CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously
November 08, 2021 06:00 ET
|
CytoDyn Inc.
Ongoing analysis of data from 28 mTNBC patients following 12 months of treatment with leronlimab is very encouraging given little-to-no effective treatment options currently VANCOUVER,...
New Study: Americans Who Get COVID-19 Information from Social Media Are More Likely to Believe Misinformation, Less Likely to Be Vaccinated
November 04, 2021 08:00 ET
|
de Beaumont Foundation
Bethesda, Maryland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Americans who consider social media influential on their perceptions about COVID-19 and vaccines are far more likely than the general population...
CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.
November 03, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Continues at Near 600% Increase
November 03, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
Federal report finds foreseeable, disproportionate COVID-19 fatalities, heavy toll for people with disabilities
October 29, 2021 11:36 ET
|
National Council on Disability
WASHINGTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Today the National Council on Disability (NCD) released a comprehensive report on COVID-19’s impact on people with disabilities, finding over 181,000...